Shire's (SHPG) Cinryze Label Expanded for Pediatric Use

Shire plc SHPG announced that the European Commission EC has approved a label extension for drug Cinryze for use in pediatrics Consequently Cinryze is now approved for routine prevention of angioedema attacks in children aged 6 years and above with severe and recurrent attacks